Vericel Corporation (NasdaqGM: VCEL)
Health Care · Biotechnology · US
$40.28
+0.45% today · +19.7% 1Y
Vericel Corporation (NasdaqGM: VCEL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.05B and employs 398 people.
Over the last twelve months the share price has gained 19.7%, trading between 28.95 and 49.32.
Tweenvest scores Vericel Corporation across four factors: quality 77/100, value 55/100, growth 89/100. Its strongest factor is growth.
VCEL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.05B
- Revenue (TTM)
- $306.30M
- P/E
- 85.49
- EPS
- 0.47
- Dividend yield
- —
- Beta (5Y)
- 1.03
- 52-week high
- $49.32
- 52-week low
- $28.95
- Avg volume (3M)
- —
- Shares outstanding
- 51.21M
- Employees
- 398
- Next earnings
- —
About Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
- ISIN
- US92346J1088
- Founded
- 1989
- Listed since
- Feb 4, 1997
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Duality Biotherapeutics, Inc.SEHK: 9606 | $2.11B | HK$182.70 | -6.64% |
| Novavax, Inc.NasdaqGS: NVAX | $2.10B | $12.55 | -1.61% |
| Mineralys Therapeutics, Inc.NasdaqGS: MLYS | $2.07B | $22.31 | -4.54% |
| AlvotechNasdaqGM: ALVO | $2.06B | $5.52 | -4.58% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.02B | CN¥37.86 | -4.97% |
| Genus plcLSE: GNS | $2.02B | £22.72 | -0.35% |
| Palvella Therapeutics, Inc.NasdaqGM: PVLA | $2.00B | $132.89 | -4.24% |
Figures last refreshed Oct 11, 2026.